TY - JOUR
T1 - Gastro-oesophageal reflux disease
AU - Bredenoord, Albert J.
AU - Pandolfino, John E.
AU - Smout, André J.P.M.
N1 - Funding Information:
AJB has received research funding from Shire/Movetis and Endostim and payment for development of educational presentations from MMS International. JEP has participated in educational programmes organised and sponsored by Given Imaging, has acted as a consultant for Given Imaging and Sandhill Scientific, and has received research grants from Given Imaging. AJPMS has received consultation fees from XenoPort and Reckitt Benckiser and sponsorship for an educational meeting from Shire/Movetis, MMS international, and Given Imaging.
Copyright:
Copyright 2021 Elsevier B.V., All rights reserved.
PY - 2013/6/1
Y1 - 2013/6/1
N2 - Gastro-oesophageal reflux disease is one of the most common disorders of the gastrointestinal tract. Over past decades, considerable shifts in thinking about the disease have taken place. At a time when radiology was the only diagnostic test available, reflux disease was regarded as synonymous with hiatus hernia. After the advent of the flexible endoscope, reflux disease was, for a period, equated to oesophagitis. The introduction of oesophageal pH monitoring made us believe that reflux disease could be defined by an abnormally high proportion of time with oesophageal pH less than 4. Moreover, the successive arrival of histamine-2-receptor antagonists and proton-pump inhibitors changed our idea of treatment for the disease, with swings from and towards surgery, endoscopic techniques, and alternative pharmaceutical options.
AB - Gastro-oesophageal reflux disease is one of the most common disorders of the gastrointestinal tract. Over past decades, considerable shifts in thinking about the disease have taken place. At a time when radiology was the only diagnostic test available, reflux disease was regarded as synonymous with hiatus hernia. After the advent of the flexible endoscope, reflux disease was, for a period, equated to oesophagitis. The introduction of oesophageal pH monitoring made us believe that reflux disease could be defined by an abnormally high proportion of time with oesophageal pH less than 4. Moreover, the successive arrival of histamine-2-receptor antagonists and proton-pump inhibitors changed our idea of treatment for the disease, with swings from and towards surgery, endoscopic techniques, and alternative pharmaceutical options.
UR - http://www.scopus.com/inward/record.url?scp=84878306718&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84878306718&partnerID=8YFLogxK
U2 - 10.1016/S0140-6736(12)62171-0
DO - 10.1016/S0140-6736(12)62171-0
M3 - Review article
C2 - 23477993
AN - SCOPUS:84878306718
VL - 381
SP - 1933
EP - 1942
JO - The Lancet
JF - The Lancet
SN - 0140-6736
IS - 9881
ER -